pyridostigmine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
acetylcholinesterase inhibitors 2330 155-97-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pyridostigmine
  • pyridostigmine bromide
  • pyridostigmine iodide
A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.
  • Molecular weight: 181.21
  • Formula: C9H13N2O2
  • CLOGP: -4.26
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 33.42
  • ALOGS: -2.32
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.18 g O
10 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 52 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 85 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 76.59 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 7.60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.50 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,STK33,TEK 32
kinase-selectivity-class AXL,BRAF,CDK9,DDR1,GRK2,MAP2K6,MAPK7,MARK4,SIK2,STK33,TEK,TTK 12
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
April 6, 1955 FDA VALEANT PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myasthenia gravis 896.97 15.63 199 10664 6626 90610958
Myasthenia gravis crisis 547.07 15.63 97 10766 967 90616617
Eyelid ptosis 116.60 15.63 43 10820 8963 90608621
Diplopia 115.09 15.63 60 10803 28654 90588930
Off label use 114.56 15.63 339 10524 1101913 89515671
Thymoma 95.30 15.63 18 10845 260 90617324
Dysphagia 54.13 15.63 67 10796 112211 90505373
Postural orthostatic tachycardia syndrome 45.41 15.63 15 10848 2257 90615327
Myasthenic syndrome 43.66 15.63 10 10853 382 90617202
COVID-19 43.62 15.63 75 10788 168768 90448816
Speech disorder 43.17 15.63 39 10824 45546 90572038
Bradycardia 41.96 15.63 51 10812 83796 90533788
Adiposis dolorosa 40.33 15.63 9 10854 305 90617279
Meningitis aseptic 38.60 15.63 18 10845 6755 90610829
Muscular weakness 37.53 15.63 79 10784 206587 90410997
Drug ineffective 36.32 15.63 286 10577 1384012 89233572
Nocardiosis 35.97 15.63 13 10850 2557 90615027
Cerebral toxoplasmosis 35.15 15.63 11 10852 1394 90616190
Oromandibular dystonia 34.50 15.63 9 10854 594 90616990
Diaphragmatic paralysis 33.22 15.63 9 10854 687 90616897
Blood pressure increased 33.06 15.63 73 10790 197144 90420440
Glucose tolerance impaired 32.88 15.63 17 10846 7968 90609616
Drug ineffective for unapproved indication 32.47 15.63 40 10823 66604 90550980
Therapy non-responder 30.52 15.63 57 10806 136647 90480937
Symptom recurrence 30.52 15.63 13 10850 3946 90613638
Antiacetylcholine receptor antibody positive 28.76 15.63 6 10857 147 90617437
Cholinergic syndrome 28.59 15.63 8 10855 688 90616896
Arthropathy 28.11 15.63 5 10858 366237 90251347
Glossodynia 27.97 15.63 3 10860 321776 90295808
Brain abscess 27.68 15.63 11 10852 2801 90614783
Bulbar palsy 27.65 15.63 5 10858 56 90617528
Systemic lupus erythematosus 27.64 15.63 5 10858 361891 90255693
Ocular myasthenia 27.53 15.63 6 10857 182 90617402
Borderline leprosy 26.83 15.63 4 10859 11 90617573
Product residue present 26.32 15.63 12 10851 4279 90613305
Respiratory distress 25.08 15.63 27 10836 38919 90578665
Rebound effect 24.99 15.63 15 10848 9369 90608215
Asthenia 24.94 15.63 128 10735 533623 90083961
Respiratory failure 24.73 15.63 48 10815 118370 90499214
Product substitution issue 24.50 15.63 19 10844 17989 90599595
Arteriospasm coronary 24.45 15.63 12 10851 5038 90612546
Thymectomy 24.09 15.63 3 10860 0 90617584
Acute on chronic liver failure 23.99 15.63 6 10857 334 90617250
Dysarthria 23.84 15.63 31 10832 54451 90563133
Wound 23.54 15.63 4 10859 302976 90314608
Menopause 22.64 15.63 10 10853 3311 90614273
Wrong patient received product 22.20 15.63 10 10853 3467 90614117
Sinoatrial block 21.56 15.63 7 10856 998 90616586
Suspected COVID-19 21.30 15.63 9 10854 2677 90614907
Hepatitis B surface antibody positive 20.88 15.63 5 10858 232 90617352
Supine hypertension 20.79 15.63 4 10859 64 90617520
Solar lentigo 20.46 15.63 7 10856 1173 90616411
Sensory disturbance 20.40 15.63 16 10847 15397 90602187
Salivary hypersecretion 20.32 15.63 13 10850 9079 90608505
Apnoea 19.91 15.63 13 10850 9401 90608183
Myocardial necrosis marker increased 19.64 15.63 8 10855 2170 90615414
Oral fungal infection 19.44 15.63 9 10854 3323 90614261
Hepatitis B core antibody positive 18.93 15.63 5 10858 346 90617238
Varicella 18.89 15.63 8 10855 2394 90615190
Alopecia 18.78 15.63 19 10844 495052 90122532
Headache 18.63 15.63 171 10692 862575 89755009
Torticollis 18.40 15.63 8 10855 2550 90615034
Lower respiratory tract infection 18.01 15.63 4 10859 250655 90366929
Gastric infection 17.92 15.63 9 10854 3971 90613613
Listeriosis 17.79 15.63 7 10856 1736 90615848
Psoriatic arthropathy 17.76 15.63 3 10860 228332 90389252
Ophthalmic herpes zoster 17.74 15.63 8 10855 2780 90614804
Osmophobia 17.61 15.63 4 10859 147 90617437
Transfusion-related circulatory overload 17.43 15.63 4 10859 154 90617430
Chronic inflammatory demyelinating polyradiculoneuropathy 17.33 15.63 6 10857 1041 90616543
Joint swelling 17.24 15.63 21 10842 503279 90114305
Lack of infusion site rotation 17.21 15.63 4 10859 163 90617421
Condition aggravated 17.12 15.63 126 10737 595419 90022165
SARS-CoV-2 test negative 16.73 15.63 5 10858 543 90617041
Enteritis 16.51 15.63 12 10851 10309 90607275
Cartilage injury 16.43 15.63 7 10856 2124 90615460
Increased bronchial secretion 16.36 15.63 7 10856 2146 90615438
Impaired healing 16.31 15.63 4 10859 234195 90383389
No adverse event 15.98 15.63 29 10834 67953 90549631
Thermal burn 15.94 15.63 10 10853 6752 90610832

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myasthenia gravis crisis 335.12 16.48 65 6929 781 42613560
Myasthenia gravis 333.64 16.48 118 6876 16019 42598322
Eyelid ptosis 189.73 16.48 62 6932 6599 42607742
Diplopia 125.75 16.48 63 6931 20253 42594088
Off label use 60.87 16.48 235 6759 638100 41976241
Myasthenic syndrome 55.84 16.48 15 6979 806 42613535
Muscular weakness 48.53 16.48 64 6930 83434 42530907
Respiratory failure 48.18 16.48 80 6914 128052 42486289
Intestinal transit time decreased 47.52 16.48 9 6985 94 42614247
Glucose tolerance impaired 41.75 16.48 18 6976 4106 42610235
Histoplasmosis 36.60 16.48 13 6981 1774 42612567
Product residue present 34.11 16.48 14 6980 2827 42611514
Osteoporosis 33.29 16.48 24 6970 14882 42599459
Thymoma 32.13 16.48 7 6987 153 42614188
Ocular myasthenia 32.09 16.48 9 6985 568 42613773
Drug ineffective 31.42 16.48 193 6801 630004 41984337
Morvan syndrome 30.53 16.48 5 6989 20 42614321
Ophthalmoplegia 30.42 16.48 12 6982 2188 42612153
Blood bromide increased 28.06 16.48 5 6989 36 42614305
Wrong patient received product 27.85 16.48 13 6981 3570 42610771
Dysphagia 26.74 16.48 45 6949 72674 42541667
Cholinergic syndrome 26.40 16.48 8 6986 663 42613678
Eye luxation 26.15 16.48 4 6990 9 42614332
Asthenia 25.36 16.48 102 6892 280691 42333650
Meningitis aseptic 22.25 16.48 12 6982 4470 42609871
Salivary hypersecretion 20.81 16.48 16 6978 10927 42603414
Myiasis 20.77 16.48 4 6990 46 42614295
Cerebral toxoplasmosis 20.72 16.48 9 6985 2089 42612252
Myopathy 19.59 16.48 17 6977 13744 42600597
Lip swelling 18.43 16.48 19 6975 19034 42595307
Faecal vomiting 17.92 16.48 6 6988 686 42613655
Respiratory muscle weakness 16.96 16.48 4 6990 126 42614215
Rebound effect 16.74 16.48 12 6982 7367 42606974
Symptom recurrence 16.73 16.48 7 6987 1483 42612858
Rash scarlatiniform 16.50 16.48 4 6990 142 42614199

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myasthenia gravis 944.17 14.23 270 15507 21241 110552281
Myasthenia gravis crisis 773.55 14.23 145 15632 1669 110571853
Eyelid ptosis 255.45 14.23 89 15688 13238 110560284
Diplopia 174.00 14.23 95 15682 41799 110531723
Off label use 160.50 14.23 522 15255 1499663 109073859
Thymoma 113.72 14.23 23 15754 401 110573121
Myasthenic syndrome 93.36 14.23 24 15753 1252 110572270
Glucose tolerance impaired 75.81 14.23 34 15743 9803 110563719
Drug ineffective 68.49 14.23 409 15368 1520131 109053391
Dysphagia 66.43 14.23 95 15682 153505 110420017
Respiratory failure 65.12 14.23 113 15664 215219 110358303
Ocular myasthenia 58.71 14.23 15 15762 763 110572759
Muscular weakness 58.37 14.23 117 15660 248351 110325171
Cerebral toxoplasmosis 56.42 14.23 20 15757 3122 110570400
Cholinergic syndrome 55.13 14.23 16 15761 1316 110572206
Wrong patient received product 51.21 14.23 23 15754 6651 110566871
Intestinal transit time decreased 46.62 14.23 9 15768 122 110573400
Drug ineffective for unapproved indication 46.50 14.23 65 15712 102773 110470749
Meningitis aseptic 45.48 14.23 24 15753 9846 110563676
Rebound effect 41.40 14.23 26 15751 14780 110558742
Bradycardia 39.85 14.23 76 15701 155441 110418081
Ophthalmoplegia 39.76 14.23 16 15761 3534 110569988
Adiposis dolorosa 38.77 14.23 9 15768 305 110573217
Salivary hypersecretion 37.54 14.23 26 15751 17395 110556127
Speech disorder 35.72 14.23 44 15733 61525 110511997
COVID-19 34.04 14.23 94 15683 244966 110328556
Nocardiosis 33.92 14.23 18 15759 7468 110566054
Therapy non-responder 33.29 14.23 71 15706 157236 110416286
Bulbar palsy 32.33 14.23 8 15769 357 110573165
Product residue present 31.58 14.23 14 15763 3927 110569595
Morvan syndrome 31.23 14.23 5 15772 20 110573502
Blood pressure increased 30.96 14.23 94 15683 258279 110315243
Postural orthostatic tachycardia syndrome 30.11 14.23 11 15766 1871 110571651
Asthenia 29.26 14.23 183 15594 688816 109884706
Dysarthria 29.20 14.23 47 15730 84074 110489448
Blood bromide increased 28.76 14.23 5 15772 36 110573486
Histoplasmosis 28.62 14.23 12 15765 2941 110570581
Arteriospasm coronary 28.03 14.23 17 15760 9083 110564439
Respiratory distress 27.43 14.23 41 15736 68833 110504689
Oromandibular dystonia 26.70 14.23 9 15768 1210 110572312
Suspected COVID-19 26.68 14.23 12 15765 3481 110570041
Pulmonary nocardiosis 26.54 14.23 11 15766 2618 110570904
Diaphragmatic paralysis 26.17 14.23 9 15768 1285 110572237
Osteopenia 25.77 14.23 23 15754 22186 110551336
Eye luxation 25.19 14.23 4 15773 15 110573507
Sensory disturbance 24.19 14.23 20 15757 17409 110556113
Antiacetylcholine receptor antibody positive 24.11 14.23 6 15771 274 110573248
Atrioventricular block complete 23.71 14.23 21 15756 20061 110553461
Thymectomy 23.57 14.23 3 15774 0 110573522
Menopause 23.55 14.23 10 15767 2528 110570994
Arthropathy 23.52 14.23 6 15771 287516 110286006
Symptom recurrence 23.12 14.23 12 15765 4760 110568762
Therapy partial responder 22.33 14.23 27 15750 37034 110536488
Congenital myasthenic syndrome 21.49 14.23 3 15774 3 110573519
Acute on chronic liver failure 21.48 14.23 6 15771 430 110573092
No adverse event 21.31 14.23 38 15739 73801 110499721
Pericarditis 21.25 14.23 3 15774 219111 110354411
Myiasis 21.02 14.23 4 15773 50 110573472
Neutropenia 20.74 14.23 14 15763 374606 110198916
Borderline leprosy 20.47 14.23 4 15773 58 110573464
Blister 20.09 14.23 4 15773 227372 110346150
Lower respiratory tract infection 20.03 14.23 5 15772 243101 110330421
Pneumonia aspiration 19.94 14.23 39 15738 81194 110492328
Systemic lupus erythematosus 19.52 14.23 6 15771 254332 110319190
Brain abscess 19.20 14.23 12 15765 6762 110566760
Psoriatic arthropathy 18.38 14.23 3 15774 196758 110376764
Irritability 18.38 14.23 28 15749 47781 110525741
Condition aggravated 18.14 14.23 172 15605 734664 109838858
Acute kidney injury 18.01 14.23 40 15737 635390 109938132
Stomatitis 18.00 14.23 8 15769 270234 110303288
Hepatitis B surface antibody positive 17.97 14.23 5 15772 353 110573169
Cyanopsia 17.97 14.23 4 15773 112 110573410
Sinoatrial block 17.79 14.23 7 15770 1458 110572064
Solar lentigo 17.52 14.23 7 15770 1517 110572005
Respiratory muscle weakness 17.18 14.23 5 15772 415 110573107
Wound 17.16 14.23 6 15771 234431 110339091
Osmophobia 17.14 14.23 4 15773 139 110573383
Coma 17.13 14.23 46 15731 117823 110455699
Drug effective for unapproved indication 17.09 14.23 15 15762 14152 110559370
Platelet count decreased 16.69 14.23 6 15771 230437 110343085
Myocardial necrosis marker increased 16.65 14.23 9 15768 3871 110569651
Lack of infusion site rotation 16.64 14.23 4 15773 158 110573364
Myopathy 16.38 14.23 19 15758 24941 110548581
Listeriosis 16.34 14.23 8 15769 2806 110570716
Wheezing 16.31 14.23 8 15769 255222 110318300
Impaired healing 16.29 14.23 4 15773 196713 110376809
Product substitution issue 15.89 14.23 18 15759 23043 110550479
Dropped head syndrome 15.87 14.23 5 15772 543 110572979
Gastric infection 15.86 14.23 9 15768 4257 110569265
Oral fungal infection 15.50 14.23 9 15768 4443 110569079
Respiratory acidosis 15.41 14.23 14 15763 13812 110559710
Torticollis 15.32 14.23 8 15769 3213 110570309
Thermal burn 15.08 14.23 11 15766 7977 110565545
Chronic inflammatory demyelinating polyradiculoneuropathy 15.06 14.23 7 15770 2188 110571334
Joint swelling 15.05 14.23 25 15752 442820 110130702
Hepatitis B core antibody positive 14.96 14.23 5 15772 654 110572868
Diabetes mellitus 14.66 14.23 39 15738 99342 110474180

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07AA02 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
PARASYMPATHOMIMETICS
Anticholinesterases
FDA MoA N0000000177 Cholinesterase Inhibitors
MeSH PA D002800 Cholinesterase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
FDA EPC N0000175723 Cholinesterase Inhibitor
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:50514 vasoconstrictor agent
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:55324 gastrointestinal drug

Related Drugs by ATC class:

N07AA Anticholinesterases 3 drugs
ambenoniumdistigmineneostigmine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Myasthenia gravis indication 91637004 DOID:437
Neuromuscular Block due to Nondepolarizing Drug indication
Prevention of Nerve Agent Poisoning indication
Urinary tract obstruction contraindication 7163005 DOID:5200
Kidney disease contraindication 90708001 DOID:557
Gastrointestinal obstruction contraindication 126765001
Asthma contraindication 195967001 DOID:2841




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
105MG PYRIDOSTIGMINE BROMIDE AMNEAL N217604 Oct. 4, 2024 DISCN TABLET, EXTENDED RELEASE ORAL 11478425 June 18, 2038 PRETREATMENT AGAINST THE LETHAL EFFECTS OF SOMAN NERVE AGENT POISONING

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Acetylcholinesterase Enzyme INHIBITOR IC50 6.44 CHEMBL CHEMBL
Cholinesterase Enzyme Ki 5.46 CHEMBL
Acetylcholinesterase Enzyme IC50 7.09 CHEMBL
Acetylcholinesterase Enzyme Ki 4.71 CHEMBL

External reference:

IDSource
4019921 VUID
N0000148006 NUI
D00487 KEGG_DRUG
101-26-8 SECONDARY_CAS_RN
4017783 VANDF
4019921 VANDF
C0034261 UMLSCUI
CHEBI:8665 CHEBI
CHEMBL1115 ChEMBL_ID
DB00545 DRUGBANK_ID
CHEMBL812 ChEMBL_ID
D011729 MESH_DESCRIPTOR_UI
4991 PUBCHEM_CID
8994 IUPHAR_LIGAND_ID
19QM69HH21 UNII
9000 RXNORM
46043 MMSL
5392 MMSL
d00363 MMSL
001707 NDDF
004687 NDDF
34915005 SNOMEDCT_US
373344003 SNOMEDCT_US
59953007 SNOMEDCT_US
4685-03-4 SECONDARY_CAS_RN
278 INN_ID
19QM69HH21 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0115-1404 TABLET, EXTENDED RELEASE 180 mg ORAL ANDA 12 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0115-2134 TABLET 30 mg ORAL ANDA 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0115-3511 TABLET 60 mg ORAL ANDA 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0115-3511 TABLET 60 mg ORAL ANDA 11 sections
Mestinon HUMAN PRESCRIPTION DRUG LABEL 1 0187-3010 TABLET 60 mg ORAL NDA 15 sections
Mestinon HUMAN PRESCRIPTION DRUG LABEL 1 0187-3012 SOLUTION 60 mg ORAL NDA 15 sections
Mestinon HUMAN PRESCRIPTION DRUG LABEL 1 0187-3013 TABLET, EXTENDED RELEASE 180 mg ORAL NDA 15 sections
Regonol HUMAN PRESCRIPTION DRUG LABEL 1 0781-3040 INJECTION, SOLUTION 5 mg INTRAVENOUS NDA 19 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6622 TABLET 60 mg ORAL ANDA 11 sections
Pryidostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 16571-833 SOLUTION 60 mg ORAL ANDA 11 sections
PRYIDOSTIGMINE BROMIDE HUMAN PRESCRIPTION DRUG LABEL 1 24689-104 SOLUTION 60 mg ORAL ANDA 14 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 42192-626 SOLUTION 60 mg ORAL ANDA 14 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 47781-335 TABLET, EXTENDED RELEASE 180 mg ORAL ANDA 12 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 47781-335 TABLET, EXTENDED RELEASE 180 mg ORAL ANDA 12 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 51407-590 TABLET 60 mg ORAL ANDA 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 58657-810 TABLET 30 mg ORAL ANDA 13 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 58657-810 TABLET 30 mg ORAL ANDA 13 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 58657-811 TABLET 60 mg ORAL ANDA 13 sections
Pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 60846-559 TABLET, EXTENDED RELEASE 105 mg ORAL NDA 29 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 62559-470 TABLET 60 mg ORAL ANDA 13 sections
Pyridostigmine Bromide Human Prescription Drug Label 1 64980-220 TABLET 180 mg ORAL ANDA 9 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 65841-819 TABLET 60 mg ORAL ANDA 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 66689-406 SOLUTION 60 mg ORAL ANDA 12 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 68084-494 TABLET 60 mg ORAL ANDA 15 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 68382-659 TABLET 60 mg ORAL ANDA 11 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 68682-301 TABLET, EXTENDED RELEASE 180 mg ORAL NDA authorized generic 12 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 68682-302 TABLET 60 mg ORAL NDA authorized generic 12 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 68682-307 SOLUTION 60 mg ORAL NDA authorized generic 15 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 69238-1731 SOLUTION 60 mg ORAL ANDA 11 sections
Pyridostigmine Human Prescription Drug Label 1 70954-148 SOLUTION 60 mg ORAL ANDA 13 sections